Showing 3921-3930 of 7767 results for "".
- Tirbanibulin Approved for Actinic Keratosishttps://practicaldermatology.com/news/tirbanibulin-approved-actinic-keratosis/2466999/The U.S. Food and Drug Administration (FDA) has approved tirbanibulin (Klisyri, Almirall) for the treatment of actinic keratosis on an expanded area of the scalp and face, according to a news release from the manufacturer. The tirbanibulin ointment, 1% is a microtubule inhibitor with a f
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l
- Lebrikizumab Maintains Efficacy Through 52 Weekshttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-through-52-weeks/2466977/New data from a pooled analysis of the ADvocate1 and ADvocate2 trials indicates lebrikizumab was efficacious for treating atopic dermatitis (AD) over a year-long period. “Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient reported ou
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areatahttps://practicaldermatology.com/news/equillium-announces-positive-topline-data-phase-2-study-eq101-alopecia-areata/2466936/Equillium announced positive topline data from its phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA). The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101, as well as
- Video-assisted Rhino-Septoplasty Technique Shows Validity: Studyhttps://practicaldermatology.com/news/video-assisted-rhino-septoplasty-technique-shows-validity-study/2466916/A new study suggests a video-guided rhino-septoplasty technique showed promise compared with more traditional techniques. "Conservative techniques have been developed in the field of rhinoplasty, focusing on limited tissue resection while emphasizing the reshaping of nasal structural elem
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- Dapsone Gel Shows Promise for Treating Acne in Skin of Colorhttps://practicaldermatology.com/news/dapsone-gel-shows-promise-treating-acne-skin-color/2463234/A new study in the Journal of Drugs in Dermatology indicates that dapsone gel, 7.5% (Aczone®, Almirall) was safe and effective in the treatment of acne vulgaris in patients with skin of color. "Acne vulgaris is a common skin disease prevalent in skin of color patients
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://practicaldermatology.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i